Holen Sie sich die Stockscreener-App
97.77
3.60%
-3.50
Schlusskurs vom Vortag:
$101.27
Offen:
$99.94
24-Stunden-Volumen:
453.97K
Relative Volume:
0.23
Marktkapitalisierung:
$19.45B
Einnahmen:
$4.81B
Nettoeinkommen (Verlust:
$1.19B
KGV:
16.40
EPS:
5.961
Netto-Cashflow:
$1.17B
1W Leistung:
-3.20%
1M Leistung:
-4.92%
6M Leistung:
+13.54%
1J Leistung:
+32.82%
1-Tages-Spanne:
$97.54
$101.00
1-Wochen-Bereich:
$97.31
$102.25
52-Wochen-Spanne:
$53.56
$112.29
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
97.75 | 20.15B | 4.81B | 1.19B | 1.17B | 5.961 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.39 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
786.50 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
757.80 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
311.59 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-01-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Lilly and Incyte’s Olumiant Recommended in EU for Adolescents with Severe Alopecia Areata - Contract Pharma
INCY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Hair-loss pill helps 42% of teens regrow scalp hair in Lilly trial - Stock Titan
Andra AP fonden Boosts Stake in Incyte Corporation $INCY - MarketBeat
NICE backs approval for Incyte’s Opzelura - The Pharma Letter
Incyte Earnings Underscore Shift From Jakafi Reliance To Broader Pipeline - Yahoo Finance
INCYTE (INCY) R&D president exercises options, sells 18,668 shares at $100.91 - Stock Titan
Does Incyte’s 2025 Beat And 2026 Guidance Shift The Bull Case For INCY? - Yahoo Finance
Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals - ChartMill
Incyte Stock Fell 7% Last Week. Here’s What the Rest of 2026 Could Look Like - TIKR.com
Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales - Finviz
Aberdeen Group plc Grows Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte Reports $5.14 Billion in 2025 Revenue, Issues 2026 Outlook - MyChesCo
Where is Incyte Corporation (INCY) Headed According to Analysts? - Finviz
Barclays Analyst Raises Price Target for Incyte (INCY) to $117 | - GuruFocus
Incyte (INCY) Expands Latin American Partnership with Knight The - GuruFocus
The Top 5 Analyst Questions From Incyte's Q4 Earnings Call - Finviz
Incyte to Present at Upcoming Investor Conferences - Business Wire
The Top 5 Analyst Questions From Incyte’s Q4 Earnings Call - Yahoo Finance
Incyte’s Opzelura Opportunity Is Getting Bigger—How Much Upside Does Moderate AD Unlock Internationally? - Smartkarma
Do Wall Street analysts like Incyte Corporation stock? - MSN
INCY Q4 earnings miss estimates, revenues beat on higher product sales - MSN
Cookson Peirce & Co. Inc. Acquires Shares of 11,331 Incyte Corporation $INCY - MarketBeat
Incyte’s weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns (Feb 10) By Reuters - Investing.com
Incyte's weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns - Reuters
Is It Too Late To Consider Incyte (INCY) After Its 43% One Year Rally - Yahoo Finance
Incyte Corporation $INCY Shares Sold by Sound Shore Management Inc CT - MarketBeat
LSV Asset Management Buys 124,266 Shares of Incyte Corporation $INCY - MarketBeat
Illinois Municipal Retirement Fund Sells 15,073 Shares of Incyte Corporation $INCY - MarketBeat
Do Wall Street Analysts Like Incyte Corporation Stock? - Barchart.com
INCY: Stifel Raises Price Target to $120, Maintains Buy Rating | - GuruFocus
Incyte shifts course on downtown Wilmington project, sells Bracebridge buildings as state incentives face scrutiny - Delaware LIVE News
Incyte selling buildings and cutting back space at future downtown headquarters - Delaware Business Now
Do financial experts on Wall Street have a favorable opinion of Incyte Corporation shares? - Bitget
Incyte selling buildings and cut back space at future downtown headquarters - Delaware Business Now
Royal Bank Of Canada Cuts Incyte (NASDAQ:INCY) Price Target to $92.00 - MarketBeat
Incyte (INCY): RBC Capital Lowers Price Target to USD 92 | INCY Stock News - GuruFocus
Incyte (INCY) Analyst Ratings Update: Wells Fargo Lowers Price T - GuruFocus
Wells Fargo & Company Cuts Incyte (NASDAQ:INCY) Price Target to $101.00 - MarketBeat
INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow - Finviz
Incyte Corporation (NASDAQ:INCY) Q4 2025 Earnings Call Transcript - Insider Monkey
INCY: HC Wainwright & Co. Reiterates Buy Rating, Maintains $135 Price Target | INCY Stock News - GuruFocus
Incyte Faces Growing Pains As It Looks To Build Post-Jakafi Foundation - Citeline News & Insights
Incyte Shares Surge on Strong Revenue Performance and Pipeline Progress - AD HOC NEWS
Incyte Faces Jakafi Patent Cliff; Focus on Opzelura and Advancing Pipeline to Offset Losses - Morningstar
Decoding Incyte Corp (INCY): A Strategic SWOT Insight - GuruFocus
Incyte: Fourth Quarter Earnings Overview - Bitget
Incyte (INCY) Shares Fall After Q4 Earnings Miss and Weak 2026 O - GuruFocus
Incyte Corporation Reports Strong 2025 Fiscal Results and Provides 2026 Guidance - AlphaStreet News
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Incyte Corp-Aktie (INCY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| CAGNONI PABLO J | President, R&D |
Feb 19 '26 |
Sale |
100.91 |
18,668 |
1,883,788 |
234,800 |
1.10%
0.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):